StockData
Cumberland Pharmaceuticals Inc logo

Cumberland Pharmaceuticals Inc (CPIX) stock

CPIXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30225% above fair value
$5.80+0.59 (+11.32%)

Close on Nov 17, 2026Market cap $86.90MP/E –Yield –

Cumberland Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cumberland Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$9.63M. For fiscal 2025 it was -$2.79M. The highest annual figure on record is $9.85M in fiscal 2011.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.79M–
FY2024Dec 31, 2024-$6.43M–
FY2023Dec 31, 2023-$9.55M–
FY2022Dec 31, 2022-$5.70M–
FY2021Dec 31, 2021-$7.68M–
FY2020Dec 31, 2020-$6.38M–
FY2019Dec 31, 2019-$9.29M–
FY2018Dec 31, 2018-$11.17M–
FY2017Dec 31, 2017-$4.08M–
FY2016Dec 31, 2016-$1.43M-228.9%
FY2015Dec 31, 2015$1.11M-68.8%
FY2014Dec 31, 2014$3.56M–
FY2013Dec 31, 2013-$3.80M-143.1%
FY2012Dec 31, 2012$8.82M-10.5%
FY2011Dec 31, 2011$9.85M+51.5%
FY2010Dec 31, 2010$6.50M+12.6%
FY2009Dec 31, 2009$5.78M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.16M–
Q1 FY2026Mar 31, 2026-$3.13M-342.2%
Q4 FY2025Dec 31, 2025-$1.37M–
Q3 FY2025Sep 30, 2025-$1.97M–
Q2 FY2025Jun 30, 2025-$3.12M–
Q1 FY2025Mar 31, 2025$1.29M–
Q4 FY2024Dec 31, 2024-$1.84M–
Q3 FY2024Sep 30, 2024-$1.69M–
Q2 FY2024Jun 30, 2024-$1.03M-4591.4%
Q1 FY2024Mar 31, 2024-$1.87M–
Q4 FY2023Dec 31, 2023-$6.18M–
Q3 FY2023Sep 30, 2023-$1.87M–
Q2 FY2023Jun 30, 2023$22.86K–
Q1 FY2023Mar 31, 2023-$1.53M–
Q4 FY2022Dec 31, 2022-$2.28M–
Q3 FY2022Sep 30, 2022-$288.59K–
Q2 FY2022Jun 30, 2022-$1.85M–
Q1 FY2022Mar 31, 2022-$1.29M–
Q4 FY2021Dec 31, 2021-$4.35M–
Q3 FY2021Sep 30, 2021-$1.56M–
Q2 FY2021Jun 30, 2021-$1.44M–
Q1 FY2021Mar 31, 2021-$324.30K–
Q4 FY2020Dec 31, 2020-$1.75M–
Q3 FY2020Sep 30, 2020-$1.21M–
Q2 FY2020Jun 30, 2020-$1.58M–
Q1 FY2020Mar 31, 2020-$1.85M–
Q4 FY2019Dec 31, 2019-$3.39M–
Q3 FY2019Sep 30, 2019-$3.20M–
Q2 FY2019Jun 30, 2019-$1.37M–
Q1 FY2019Mar 31, 2019-$1.32M–
Q4 FY2018Dec 31, 2018-$2.26M–
Q3 FY2018Sep 30, 2018-$1.81M–
Q2 FY2018Jun 30, 2018-$868.98K–
Q1 FY2018Mar 31, 2018-$2.45M–
Q4 FY2017Dec 31, 2017-$903.33K–
Q3 FY2017Sep 30, 2017-$839.35K-745.0%
Q2 FY2017Jun 30, 2017-$1.68M–
Q1 FY2017Mar 31, 2017-$657.80K–
Q4 FY2016Dec 31, 2016-$957.37K–
Q3 FY2016Sep 30, 2016$130.13K–

More Cumberland Pharmaceuticals figures

See a number that looks wrong?